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introduction
In the United States, much of the research is focused on developing new and expensive technologies 
and drugs that are of great scientific and clinical interest, but usually providing incremental therapeutic 
benefit. In contrast, in resource-limited countries, basic oncology care is frequently lacking. In addi-
tion, the outcomes from various chemo–radiotherapy combinations for a number of malignancies 
are unknown, as these populations have not been adequately investigated. For oncologists in these 
countries who have marginal to barely adequate resources, accrual to clinical trials is virtually non-
existent because of the complexities of social and economic issues facing their population, competing 
co-morbidities and lack of access. As a result, there is a tremendous disparity in outcomes for these 
populations, as compared to those in developed countries.
At first, it may appear odd that radiation oncologists, often associated with high-cost technology, 
would have leading role in global cancer disparities. However, radiation is a critical treatment modality 
for the majority of cancers whether the intent is curative or palliative. In fact, a single dose of palliative 
radiotherapy is more cost effective than a prolonged course of narcotics (1). In addition, for many 
solid malignancies observed in low to middle income countries (LMICs), such as breast, cervical, 
head and neck (H&N), upper GI, central nervous system (CNS), and lung cancers, radiation will 
achieve very effective palliation, and sometimes cure, even when concurrent chemotherapy cannot 
be given or when oncologic surgeons are unavailable. In addition, radiation oncology centers are 
often the hub of technologies, such as telemedicine, which can facilitate collaboration with other 
cancer centers worldwide.
The authors are privileged to be guest editors for this Frontiers Research Topic highlighting the 
issues addressing global cancer disparities. The authors have asked a number of oncologists from 
different parts of the world to report their experience and thank them for their time and work over 
the last year.
Topics covered include systematic review of radiation resources in low and middle income coun-
tries, planning national radiotherapy services, human resources for cancer control in Uttar Pradesh, 
India, locally advanced breast and cervical cancer (India, Africa), patient navigation, the challenges 
of performing clinical trials in South Africa, the cervical cancer research network (CCRN), the US 
Cancer Disparities Research Partnership (CDRP), training radiation oncologists in underserved 
parts of the world, and building sustainable partnerships through the newly formed International 
Cancer Export Corps (ICEC). The authors discuss “lessons learned” from their populations, practical 
suggestions to address these disparities, and how we as a global oncology community can address 
and potentially mitigate these global challenges.
According to the World Bank classification, 139 countries are considered LMICs as their gross 
national income (GNI) per capita is ≤USD 12,615 (2). The World Health Organization (WHO) 
report in 2010 and the United Nations declaration in 2012 chronicled the growing burden of 
non-communicable diseases (NCD) in the developing world (3, 4). In the past decade, the global 
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incidence of cancer has increased by 20%, mostly because of 
cases in LMIC (5). By 2020, up to 70% of the 20 million new cancer 
cases are expected to occur in these countries (6). Furthermore, 
these countries are not prepared to address this cancer epidemic, 
and consequently, cancer survival rates are less than one-third of 
those for site specific cancer types in high-income countries. It is 
imperative that they develop and sustain the infrastructure needed 
to prevent, diagnose, and treat this cancer “tsunami” (7). Case 
burdens are also increasing in rural underserved areas in resource-
rich countries with the native/aboriginal populations often having 
similar access and care issues as LMICs, as the Northern Plains 
American Indians (AIs) have the highest cancer mortality rate in 
the United States (8–10).
Cervical cancer is of global interest as almost 85% of the 
worldwide 530,000 cases in 2012 were diagnosed in developing 
countries. This is amenable to detection by screening and poten-
tially preventable with vaccination (11, 12). Furthermore, even 
patients with advanced stages of cervical cancer are still curable 
if appropriate radiation doses can be given with a combination of 
external beam radiation and brachytherapy (13). The social and 
economic impact is substantial as cervical cancer disproportion-
ately affects young women (14–16).
The International Atomic Energy Agency (IAEA) recommends 
a teletherapy unit, a radiation oncologist, a medical physicist, 
and two radiotherapists (RTTs) per 250,000 people (17, 18). The 
inadequacy of radiation oncology services for LMICs is reported 
by Grover et al. in a systematic review of five international data-
bases. A world map of current teletherapy units from the IAEA 
is depicted in Figure 1 from the Rosenblatt article (18). In many 
parts of Africa, there is only one teletherapy unit per 10 million 
people! The inadequacy of radiation therapy infrastructure from 
the IAEA–DIRAC database was recently reported by Datta et al. 
(19). They estimated by 2020, 84 LMICs will need 9,169 teletherapy 
units, 12,149 radiation oncologists, 9,915 medical physicists, and 
29,140 radiation therapy technologists. It is estimated that Africa 
is functioning at 25% of its potential for treating cervical cancer 
(20). These projected needs are simply staggering and cannot be 
allowed to stand.
Determining the human resources needed to treat cancer is a 
critical first step as it is important to guide investment and progress 
(21). Daphtary et al. (22) describe a unique methodology for estimat-
ing these resources needed in the state of Uttar Pradesh, India, with 
a population of 200 million. Using the publicly available sources 
of GLOBOCAN1 and city population2, they explain an enormous 
shortage of human and other resources for cancer control (12, 23). 
As the data was generated from 2008, the dilemma is expected to be 
even more dire as the cancer cases in India is projected to increase 
by 30% over the next 10 years. This case study of Uttar Pradesh may 
serve as a road map for other interested stakeholders and policy 
makers in a variety of LMICs.
Rosenblatt indicates that there should be a systematic and 
 comprehensive process of long-term planning of radiotherapy 
services at the national level, taking into account the regulatory 
1 http://globocan.iarc.fr/
2 http://www.citypopulation.de/
infrastructure for radiation protection, planning of centers, equip-
ment, staff, education programs, quality assurance, and sustainabil-
ity aspects. He adds that “realistic budgetary and cost considerations 
must also be a part of the project proposal or business plan”. 
In the second article by Grover and colleagues, the need to 
train global oncologists from the perspective of a US resident is 
presented. There is an interest and potential need for US residents 
to have global training experience, and a concomitant urgent need 
for LMIC countries to develop oncology training, infrastructure, 
and services, possibly in collaboration with US residents. Although 
limited but growing, there are international options for US residents 
including The Paul Famer Global Surgery Fellowship, international 
pediatric oncology twinning programs, travel grants through the 
American Society of Radiation Oncology (ASTRO), and the 
Global Health Scholars Program through ASTRO-Association of 
Residents in Radiation Oncology.
Although this “tsunami” of cancer in LMICs is overwhelming 
and seemingly hopeless, a recent delegation of radiation oncologists, 
residents, and medical physicists embarked on a mission to the city 
of Dakar, Senegal West Africa, to implement the first high-dose-rate 
(HDR) remote afterloader, as this country of 13 million people 
only had a single Cobalt teletherapy unit with no brachytherapy 
services. By partnering with Radiating Hope, a non-profit organiza-
tion whose mission is to update and provide radiation equipment 
to developing countries and founded by Dr. Brandon Fisher, the 
first cervical cancer patients were treated with curative intent. This 
“beacon” of hope may serve as a model and inspiration for other 
LMICs (24, 25) but is only 1/5000th or so of the need.
Conducting clinical trials for common disease sites in LMICs is 
of critical importance as the data generated from other countries 
may not be applicable for these populations. Dr. Roy Lakier, an 
oncologist from South Africa, kindly shared his data that chroni-
cled the tribulations of an IAEA sponsored phase III trial inves-
tigating radiation alone versus chemo-radiation for HIV positive 
cervical cancer patients. Even with minimal resources to conduct 
research, they successfully enrolled 81 patients. No clinically 
relevant conclusions could be drawn because of “relatively” small 
numbers and incomplete follow-up. Twenty percent of patients 
were lost to follow-up and 6% died during the first 6  months 
reflecting advanced stages of disease, impaired nutritional status, 
and significant medical co-morbidities. Their experience detailed 
several problematic areas including inadequate radiation therapy 
equipment, delays in obtaining pathology and imaging promptly, 
unavailability of chemotherapy drugs, transportation, social and 
medical co-morbidities, and non-supportive hospital policies with 
the extra research expenses incurred. Lakier and his co-workers 
are to be commended for conducting this phase III trial in a very 
resource-limited environment.
As evident by Lakier, access to cancer clinical trials is scare in 
LMICs with limited to unavailable research support and infrastruc-
ture. The Cervix Cancer Research Network (CCRN) was developed 
as a potential solution whose overall goal is to promote cervical 
cancer research and improve access to novel therapies. Of course, 
basic radiation services are a pre-requisite before novel therapies are 
considered. The CCRN is a subsidiary of the Gynecologic Cancer 
Intergroup (GCIG), and was developed under the vision of of Dr. 
Henry Kitchener from the University of Manchester. As described 
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by Suneja, 17 CCRN site visits have been performed with four 
multinational clinical trials opened that were deemed suitable. They 
suggest the use of cell phone technology to increase patient compli-
ance which was problematic in Lakier’s experience. We recently 
implemented a mobile health technology (mHealth) randomized 
trial using customized text messaging, counseling, and nicotine 
replacement to address the high smoking rates among the Northern 
Plains American Indians (26). In this resource-limited population, 
recruitment and compliance to this trial has been high. Therefore, 
the use of mHealth technology for LMIC populations for treatment 
compliance, follow-up, and clinical trials may be a potential solution.
The disparity of breast cancer in LMIC is evident as it occurs 
in younger women who present with a higher incidence of locally 
advanced breast cancer (LABC) when compared with women from 
developed countries as discussed by Balogun and Formenti. They 
make the case that “financial resources are likely better invested in 
public awareness campaigns and training community health work-
ers to educate the public and perform clinical breast exams (CBE) 
rather than screening mammography” (27–29). Basic chemothera-
peutic agents such as paclitaxel, doxorubicin, cyclophosphamide, 
and tamoxifen, rather than expensive targeted therapy such as 
herceptin, are recommended for systemic therapy. The dire need 
for adjuvant external beam radiation is discussed in the context 
of hypofractionation and concurrent with chemotherapy in order 
to maximize resources.
To increase access of underserved/health disparate communities 
to NCI clinical trials, the Radiation Research Program (RRP) piloted 
a unique model – the Cancer Disparities Research Partnership 
(CDRP) program. CDRP targeted community hospitals with a 
 limited past NCI funding history and provided funding to establish 
the infrastructure for their clinical research program. Wong summa-
rizes the results from the initial six CDRP institutions. Key findings 
from these community-based hospitals include enrolling ~2,300 
patients to clinical trials with ~5,100 patients receiving patient navi-
gation (PN) once the infrastructure was established. Another finding 
is the need for the cooperative groups to develop clinical trials for 
locally advanced cancers observed in these disparate populations.
American Indians experience tremendous cancer disparities 
with the highest 5 year mortality rates when compared with 
other US races (10). PN is a method to mitigate this disparity as 
presented by Burhansstipanov and co-workers. According to the 
Affordable Care Act where a navigator is an “insurance broker”, the 
true model of patient navigation, as created by Freeman, is one who 
helps patients overcome barriers to accessing and using a specific 
health care system (30). Burhansstipanov describes a unique model 
of PN where navigators are AI and part of the community who 
navigate in a culturally appropriate fashion. In South Dakota, the 
authors implemented a similar model of PN for the AI community 
(Walking Forward) where they were able to document improved 
satisfaction with the health care system and improved treatment 
compliance for AIs undergoing radiation (8, 31).
international Cancer Expert Corps (iCEC): 
Building a Sustainable Global Network
Likely because of the magnitude of the problem, when global 
cancer disparities are discussed, often only the problem is 
presented, rather than solutions and a logical plan to address 
these complex economic, social, political, and healthcare inequal-
ity issues. Signaling a transformational change to respond both to 
the global need and to create a sustainable altruistic component 
to healthcare careers, Coleman and colleagues detail the newly 
formed ICEC whose goal is to reduce the mortality and improve 
the quality of life for cancer patients in LMIC. They outline key 
steps in this process including structured support for dedicated 
faculty attempting to establish a formal career path, with metrics 
for human service.
The goal for an ICEC Center, within the LMIC, or geographic-
access limited setting within resource-rich countries, as often 
encountered with indigenous populations, is to develop and 
retain a high-quality sustainable workforce who can provide 
best possible cancer care for their setting, conduct research, and 
become a regional center of excellence from which to help other 
ICEC Centers develop. An international mentoring network of 
cancer professionals, including many of the contributors to this 
issue of Frontiers, will work with local and regional in-country 
groups on projects to develop and sustain expertise and local 
solutions for better cancer care, as detailed in Figure 1 of the 
Coleman article (32). The vision is a world in which everyone 
has access to cost-effective interventions to prevent and treat 
cancer and its symptoms in ways that are consistent with best 
possible practices for the local circumstances.
Partnering with and enhancing ongoing global health 
programs and “twinning” between programs in resource-rich 
and health disparity communities is an essential tenet of ICEC 
to help create a critical mass of sustainable expertise, which is 
difficult to obtain from the independent well-intended smaller 
programs (i.e., the current model). In essence, ICEC is aiming 
to create a “public health oncology” road map to “tap into” a 
global panel of experts to mentor physicians, nurses, scientists, 
epidemiologists, and other health care and health policy workers 
from LMICs (33). Global expertise will include academicians, 
private practitioners, and senior mentors who along with their 
institution are willing to commit time so that person-to-person 
relationships will enhance investment in and quality of cancer 
care where there is a need that must be met by the global 
community.
Although cancer at the cellular and molecular level is a com-
plex disease that requires multiple interventions for a successful 
outcome, so too is cancer at the global level as multiple partners 
are required to address multiple barriers to mitigate these ongoing 
global cancer disparities. The contributors and their colleagues and 
partners in this issue of Frontiers are agents of change, addressing 
a  problem that some might consider “too hard”, or “too expen-
sive”  … and they are demonstrating that with dedication, support, 
and commitment, change will occur. Two quotes come to mind 
from those who have changed the world. Margaret Meade noted: 
“Never believe that a few caring people can’t change the world. 
For, indeed, that’s all who ever have”. The authors believe there are 
a growing number of dedicated and passionate individuals who 
will transform global oncology sometime in the not too distant 
future. The authors in the cancer community will smile when they 
think of the remark by Nelson Mandella, “It always looks hard 
until it is done!”
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